Download Sample
Add to CartOral Biologics And Biosimilars Market
By Therapy;
Lymphocyte Modulators- [T-Cell Modulators, B-Cell Modulators and Sphingosine-1-Phosphate Receptor Modulators], Interleukin Inhibitors- [IL-1 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors and IL-23 Inhibitors], Tumor Necrosis Factor-Alpha Inhibitors- [TNF-a Blockers and Monoclonal Antibodies Targeting TNF-a], Immunostimulants- [Cytokines, Immune Checkpoint Inhibitors and Adjuvants], GPCR Modulators- [Agonists, Antagonists and Biased Ligands] and OthersBy Disease;
Diabetes, Arthritis & Crohn’s Disease, Cancer, Infectious Disease and OthersBy Molecule Type;
Vaccines, Proteins & Peptides, Monoclonal Antibodies and OthersBy Distribution Channel;
Hospital Pharmacies, Retail Pharmacies and Online PharmaciesBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031)Oral Biologics and Biosimilars Market Overview
Oral Biologics and Biosimilars Market (USD Million)
Oral Biologics and Biosimilars Market was valued at USD 7,678.52 million In the year 2024. The size of this market is expected to increase to USD 27,669.58 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 20.1%.
Oral Biologics And Biosimilars Market
*Market size in USD million
CAGR 20.1 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 20.1 % |
| Market Size (2024) | USD 7,678.52 Million |
| Market Size (2031) | USD 27,669.58 Million |
| Market Concentration | Low |
| Report Pages | 358 |
Major Players
- Novartis AG
- Amgen Inc.
- Pfizer Inc.
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Biocon Ltd.
- Sandoz International GmbH (a subsidiary of Novartis)
- Celltrion Inc.
- Biogen Inc.
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Oral Biologics And Biosimilars Market
Fragmented - Highly competitive market without dominant players
Oral Biologics and Biosimilars Market is undergoing rapid transformation as therapies move from injections to oral drug delivery. Patient surveys indicate that nearly 55% prefer oral formulations for convenience and comfort. About 60% of clinical pipelines now focus on oral biologics, signaling strong research and development efforts. This trend is improving treatment adherence and accessibility for chronic conditions.
Rising Demand for Patient-Centric Solutions
Non-invasive treatments are at the forefront, with ~65% of patients more likely to adhere to therapy when oral options are available. Around 50% of healthcare providers prioritize oral biologics to boost compliance. In autoimmune treatments, nearly 45% of patients are already using oral regimens, highlighting their growing importance in long-term disease care.
Technological Advancements
Cutting-edge drug delivery platforms are accelerating the adoption of oral biologics. About 40% of formulations now incorporate nanocarrier systems and enzyme inhibitors for improved bioavailability. Biosimilars represent nearly 35% of the development pipeline, providing cost-efficient alternatives. Around 50% of next-generation products rely on targeted release technologies, improving efficacy and patient outcomes.
Integration into Clinical Practice
Oral biologics are increasingly embedded in healthcare practices, with ~55% of physicians reporting better adherence compared to injections. Nearly 45% of clinics note a reduction in injection-related infrastructure, improving efficiency. Patient management programs, adopted in ~40% of treatments, are ensuring continuous monitoring and long-term disease control.
Oral Biologics and Biosimilars Market Key Takeaways
-
Oral biologics are gaining momentum as a non-invasive alternative to injectable therapies, enhancing patient compliance and convenience in chronic disease management.
-
Bisphosphonates are leading the oral biologics segment, particularly for osteoporosis treatment, due to their efficacy and long-term safety profile.
-
FDA's accelerated approval process for biosimilars is reducing development timelines and costs, fostering market competition and affordability in biologic therapies.
-
Interchangeability designations for biosimilars, such as denosumab, are enhancing market access and therapeutic flexibility for patients and healthcare providers.
-
North America remains the dominant market for oral biologics and biosimilars, driven by high healthcare expenditure and regulatory support for biosimilar adoption.
-
India is emerging as a key player in the biosimilars market, leveraging its manufacturing capabilities and regulatory advancements to expand global market share.
-
Rising prevalence of chronic conditions and the need for cost-effective treatments are propelling the demand for oral biologics and biosimilars, aligning with global healthcare sustainability goals.
Oral Biologics and Biosimilars Market Recent Developments
-
In March 2022, Amneal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved its Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen. The product is marketed under the brand name RELEUKO, expanding Amneal’s presence in the biosimilar therapeutics market.
-
In December 2021, Gedeon Richter, Hungary’s leading pharmaceutical company, entered into an agreement with Hikma Pharmaceuticals, a London-listed drug manufacturer, to out-license its biosimilar denosumab for commercialization in the U.S.
Oral Biologics And Biosimilars Market Segment Analysis
In this report, the Oral Biologics and Biosimilars Market has been segmented by Therapy, Disease, Molecule Type, Distribution Channel, and Geography. This segmentation offers a detailed overview of the therapies and drugs that are driving growth in the biologics and biosimilars market, with an increasing focus on oral formulations for treating a variety of diseases.
Oral Biologics and Biosimilars Market, Segmentation by Therapy
The Therapy segmentation classifies oral biologics and biosimilars based on the specific mechanisms they target in the immune system or disease processes. These therapies are central to the treatment of various conditions, from autoimmune diseases to cancer and diabetes.
Lymphocyte Modulators
Lymphocyte Modulators include therapies that modulate immune cell function to treat diseases like autoimmune disorders. Key subcategories include:
-
T-Cell Modulators are used to control T-cell activation and proliferation, addressing autoimmune diseases like multiple sclerosis and rheumatoid arthritis.
-
B-Cell Modulators help in reducing B-cell activity, which is crucial in treating conditions like lupus and rheumatoid arthritis.
-
Sphingosine-1-Phosphate Receptor Modulators are utilized in autoimmune diseases to modulate lymphocyte trafficking, particularly in the treatment of multiple sclerosis.
Interleukin Inhibitors
Interleukin Inhibitors target specific interleukins that regulate immune responses, offering effective treatments for autoimmune and inflammatory diseases. These include:
-
IL-1 Inhibitors are used to treat inflammatory conditions like rheumatoid arthritis and gout.
-
IL-6 Inhibitors are important in treating diseases like rheumatoid arthritis and systemic juvenile idiopathic arthritis (SJIA).
-
IL-17 Inhibitors target IL-17 to treat conditions like psoriasis and psoriatic arthritis.
-
IL-23 Inhibitors are mainly used in the treatment of psoriasis and inflammatory bowel diseases.
Tumor Necrosis Factor-Alpha Inhibitors
Tumor Necrosis Factor-Alpha Inhibitors (TNF-a inhibitors) are widely used in the treatment of autoimmune diseases by targeting TNF-a, a key inflammatory mediator. This includes:
-
TNF-a Blockers such as infliximab and adalimumab are used to treat conditions like rheumatoid arthritis and Crohn’s disease.
-
Monoclonal Antibodies Targeting TNF-a provide more targeted therapies for conditions like ulcerative colitis and rheumatoid arthritis.
Immunostimulants
Immunostimulants are therapies that enhance the body’s immune response, crucial for treating cancer and certain infections. This category includes:
-
Cytokines like interferons and interleukins that modulate immune cell activity in the treatment of cancers and viral infections.
-
Immune Checkpoint Inhibitors such as PD-1 and CTLA-4 inhibitors that enhance T-cell-mediated immunity, used in cancer immunotherapy.
-
Adjuvants are substances that enhance the body’s immune response to vaccines or infections.
GPCR Modulators
GPCR Modulators influence G-protein-coupled receptors (GPCRs), which are involved in a variety of physiological processes. Subcategories include:
-
Agonists that activate GPCRs for therapeutic benefits in conditions like asthma and hypertension.
-
Antagonists block GPCRs to treat diseases like Parkinson’s disease and heart failure.
-
Biased Ligands offer a selective activation of GPCR pathways, providing a novel approach to drug development in chronic diseases.
Others
Other Therapies include novel biologics and biosimilars in development that aim to treat a wide range of diseases, offering potential breakthroughs in precision medicine.
Oral Biologics and Biosimilars Market, Segmentation by Disease
The Disease segmentation focuses on the specific diseases that oral biologics and biosimilars aim to treat. These diseases require targeted therapies that modulate the immune system or address genetic mutations.
Diabetes
Diabetes treatment with oral biologics focuses on improving insulin sensitivity and regulating blood glucose levels. Oral biologics, including insulin modulators, are being developed to enhance diabetes management.
Arthritis & Crohn’s Disease
Arthritis & Crohn’s Disease are treated using biologics like TNF-a inhibitors and interleukin inhibitors that target inflammation pathways and improve quality of life for patients with chronic inflammation.
Cancer
Cancer therapies targeting tumor growth, immune checkpoints, and specific cancer mutations are rapidly advancing with oral biologics that help modulate the immune system to fight cancer cells.
Infectious Disease
Infectious Disease treatment is seeing the emergence of immunostimulants and cytokines that enhance immune responses to chronic infections such as hepatitis and HIV, offering new avenues for oral treatment.
Others
Other Diseases include genetic disorders, cardiovascular diseases, and neurological conditions, where oral biologics are being explored for their potential to address complex pathophysiology and improve patient outcomes.
Oral Biologics and Biosimilars Market, Segmentation by Molecule Type
The Molecule Type segmentation distinguishes oral biologics and biosimilars based on the molecular structure and formulation, which dictate the mode of action and application in treating various diseases.
Vaccines
Vaccines are being developed as oral biologics to provide easier administration compared to injectable vaccines. These vaccines target diseases like influenza, hepatitis, and HPV, offering convenience and improved patient compliance.
Proteins & Peptides
Proteins & Peptides are used in biologics for their ability to modulate specific immune responses, address genetic disorders, and treat diseases like cancer and diabetes. Oral forms of proteins and peptides are emerging as effective treatments for chronic conditions.
Monoclonal Antibodies
Monoclonal Antibodies are a key area in biologics development, with therapies that target specific molecules or cells. Oral formulations of monoclonal antibodies are being developed for conditions like autoimmune diseases, cancer, and chronic infections.
Others
Other Molecule Types include emerging biologic modalities such as gene therapies and cell-based treatments, which are being explored for their potential to treat a wide range of genetic and chronic diseases.
Oral Biologics and Biosimilars Market, Segmentation by Distribution Channel
The Distribution Channel segmentation identifies the primary pathways through which oral biologics and biosimilars reach consumers and healthcare providers.
Hospital Pharmacies
Hospital Pharmacies are crucial distribution channels for oral biologics and biosimilars, as they serve patients requiring specialized treatments for complex conditions such as cancer, diabetes, and autoimmune diseases.
Retail Pharmacies
Retail Pharmacies offer consumers access to over-the-counter and prescription-based oral biologics. Retail pharmacies play an important role in making oral treatments more accessible to a wide range of patients.
Online Pharmacies
Online Pharmacies are becoming increasingly important in distributing oral biologics and biosimilars, particularly for patients who need convenient home delivery for chronic disease management. The growing trend of e-commerce is reshaping how these treatments are accessed.
Oral Biologics and Biosimilars Market, Segmentation by Geography
The Geography segmentation highlights regional differences in the adoption of oral biologics and biosimilars, influenced by healthcare infrastructure, market regulations, and consumer preferences.
Regions and Countries Analysed in this Report
North America
North America remains the largest market for oral biologics and biosimilars due to high healthcare expenditure, advanced research, and strong regulatory frameworks. The U.S. is at the forefront of adopting these therapies, particularly in treating autoimmune disorders, cancer, and chronic conditions.
Europe
Europe is experiencing steady growth in the market, driven by increasing adoption of biologics and biosimilars for conditions like rheumatoid arthritis and cancer. The region benefits from a well-established healthcare system and government initiatives to promote access to affordable biologic therapies.
Asia Pacific
Asia Pacific is seeing rapid market expansion, with growing healthcare access, an aging population, and increasing awareness of biologic therapies. Countries like China, India, and Japan are significant contributors to the growth of oral biologics and biosimilars in the region.
Middle East & Africa
Middle East & Africa exhibit moderate growth, with increasing healthcare investments and rising awareness of biologic therapies. However, access to advanced treatments is still limited in some parts of the region due to economic and healthcare infrastructure challenges.
Latin America
Latin America is experiencing steady demand for oral biologics and biosimilars, particularly in Brazil and Mexico, where access to cutting-edge treatments is improving, and healthcare systems are modernizing.
Oral Biologics And Biosimilars Market Forces
This report provides an in depth analysis of various factors that impact the dynamics of Oral Biologics and Biosimilars Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Comprehensive Market Impact Matrix
This matrix outlines how core market forces Drivers, Restraints, and Opportunities affect key business dimensions including Growth, Competition, Customer Behavior, Regulation, and Innovation.
| Market Forces ↓ / Impact Areas → | Market Growth Rate | Competitive Landscape | Customer Behavior | Regulatory Influence | Innovation Potential |
|---|---|---|---|---|---|
| High impact (e.g., tech adoption, rising demand) | Encourages new entrants and fosters expansion | Increases usage and enhances demand elasticity | Often aligns with progressive policy trends | Fuels R&D initiatives and product development | |
| Restraints | Slows growth (e.g., high costs, supply chain issues) | Raises entry barriers and may drive market consolidation | Deters consumption due to friction or low awareness | Introduces compliance hurdles and regulatory risks | Limits innovation appetite and risk tolerance |
| Opportunities | Unlocks new segments or untapped geographies | Creates white space for innovation and M&A | Opens new use cases and shifts consumer preferences | Policy shifts may offer strategic advantages | Sparks disruptive innovation and strategic alliances |
Drivers, Restraints and Opportunity Analysis
Drivers
- Advancements in Biotechnology
- Increasing Demand for Targeted Therapies
-
Efforts to Improve Patient Access to Biologic Treatments-Efforts to enhance patient access to biologic treatments are reshaping the global landscape of oral biologics and biosimilars market. Biologic therapies have revolutionized the treatment of various chronic diseases, offering targeted and often more effective treatment options compared to conventional pharmaceuticals. However, access to biologics has historically been limited due to factors such as high costs, complex manufacturing processes, and regulatory barriers. In response, healthcare stakeholders, including governments, insurers, and pharmaceutical companies, are implementing initiatives to improve affordability, availability, and accessibility of biologic treatments for patients worldwide.
One key strategy to improve patient access to biologic treatments is the development and commercialization of biosimilars, including oral formulations. Biosimilars are highly similar versions of approved biologic drugs, offering comparable efficacy, safety, and quality at a lower cost. By providing alternative treatment options to expensive originator biologics, biosimilars contribute to cost savings for healthcare systems and increase patient access to biologic therapies. Efforts to streamline the regulatory pathways for biosimilar approval and promote market competition have accelerated the adoption of biosimilars, driving market growth and expanding treatment options for patients with chronic diseases.
Patient assistance programs, reimbursement schemes, and pricing agreements are being implemented to address affordability barriers and improve patient access to biologic treatments, including oral formulations. Pharmaceutical companies are collaborating with healthcare providers, patient advocacy groups, and government agencies to develop innovative access programs that offer financial assistance, co-pay support, and patient education resources. Additionally, initiatives to enhance healthcare infrastructure, expand insurance coverage, and promote generic substitution policies contribute to improving patient access to biologic therapies globally. By addressing affordability and accessibility challenges, these efforts are paving the way for broader adoption of oral biologics and biosimilars, ultimately improving health outcomes and quality of life for patients with chronic diseases.
Restraints
- Technical Challenges in Oral Drug Delivery
- Regulatory Hurdles for Biosimilar Approval
-
Competition from Originator Biologics-Competition from originator biologics poses a significant challenge to the oral biologics and biosimilars market, particularly in terms of market penetration and adoption. Originator biologics, also known as reference products, are innovative therapies developed by pharmaceutical companies and protected by patents, granting them market exclusivity for a specified period. These originator biologics often have established efficacy, safety, and brand recognition, making them preferred treatment options for healthcare providers and patients. Consequently, biosimilar manufacturers face fierce competition from originator biologics when attempting to gain market share, especially in therapeutic areas with well-established biologic treatments.
Originator biologics may employ various strategies to maintain their market dominance and deter biosimilar competition. These strategies may include aggressive marketing campaigns, patent litigation, and pricing strategies such as discounts, rebates, and contracting arrangements with healthcare payers. Additionally, originator biologic manufacturers may invest in research and development efforts to extend patent protection through product improvements, reformulations, or new indications, further complicating biosimilar entry into the market. As a result, biosimilar manufacturers must navigate these competitive barriers and differentiate their products based on factors such as cost-effectiveness, accessibility, and patient outcomes to successfully compete with originator biologics.
Despite the challenges posed by competition from originator biologics, there are opportunities for biosimilar manufacturers to carve out a niche in the market and drive adoption of oral biologics and biosimilars. Regulatory initiatives aimed at increasing biosimilar approval pathways and fostering competition are creating a more favorable environment for biosimilar development and commercialization. Additionally, efforts to contain healthcare costs and improve patient access to biologic therapies are driving demand for cost-effective alternatives such as biosimilars, particularly in regions with limited healthcare budgets. With continued investment in research, development, and manufacturing capabilities, biosimilar manufacturers can capitalize on these opportunities to expand their market presence and offer patients more affordable and accessible treatment options.
Opportunities
- Expansion of Biosimilar Market
- Growing Aging Population
-
Regulatory Initiatives for Streamlined Approval Processes-Regulatory initiatives aimed at streamlining the approval processes for oral biologics and biosimilars are driving innovation and market growth within the global pharmaceutical industry. Historically, the development and approval of biosimilars have faced significant regulatory hurdles due to the complexity of biologic molecules and the challenges associated with demonstrating similarity to reference products. However, regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have implemented pathways and guidelines to expedite the approval of biosimilars, encouraging competition and increasing access to affordable biologic therapies.
These regulatory initiatives include the establishment of rigorous scientific standards for demonstrating biosimilarity, as well as expedited review processes to facilitate the approval of biosimilar products. By providing clear guidance and requirements for biosimilar development and evaluation, regulatory agencies are fostering confidence in biosimilar products among healthcare professionals and patients, accelerating their adoption in clinical practice. Additionally, initiatives such as the FDA's Biosimilar Action Plan and the EMA's Biosimilar Medicines Regulatory Network aim to promote innovation and competition in the biosimilars market while ensuring patient safety and quality standards.
Regulatory agencies are actively engaging with stakeholders, including pharmaceutical companies, healthcare providers, and patient advocacy groups, to address challenges and identify opportunities for improvement in the regulatory framework for biosimilars. By fostering collaboration and dialogue, regulatory agencies can gather valuable insights into the needs and priorities of stakeholders, inform regulatory decision-making, and enhance the efficiency and effectiveness of biosimilar regulation. As a result, streamlined approval processes for oral biologics and biosimilars are expected to spur innovation, increase market competition, and ultimately improve patient access to affordable and high-quality biologic therapies globally.
Oral Biologics And Biosimilars Market Competitive Landscape Analysis
Oral Biologics and Biosimilars Market is defined by competition among pharmaceutical companies, biotech firms, and regional distributors. Companies adopt strategies such as mergers, partnerships, and collaboration to enhance efficacy, safety, and bioavailability. With nearly 60% of share concentrated among leading players, continuous innovation in formulation technologies, delivery mechanisms, and therapeutic applications drives steady growth across autoimmune, oncology, and chronic disease treatments.
Market Structure and Concentration
The industry demonstrates moderate concentration, with about 55% of revenues controlled by multinational oral biologics and biosimilar manufacturers. Regional producers contribute to expansion through niche formulations and cost-effective therapies. This combination of consolidated leadership and fragmented innovation shapes competitive strategies, ensuring consistent growth in oral biologics and biosimilar adoption.
Brand and Channel Strategies
Leading firms strengthen their brands through partnerships with hospitals, collaborations with specialty clinics, and direct contracts with healthcare providers. Nearly 60% of adoption occurs via hospital pharmacies, while online pharmacies and specialty distribution channels support channel expansion. Effective strategies emphasize efficacy, safety, and patient adherence, reinforcing sustainable growth in the market.
Innovation Drivers and Technological Advancements
Ongoing innovation focuses on enhanced oral bioavailability, nanocarrier-based delivery, and patient-friendly formulations. Around 45% of R&D investments target technological advancements that improve therapeutic efficacy, reduce side effects, and enhance patient compliance. Strategic collaboration between manufacturers and research institutions drives strategies, enabling measurable growth in oral biologics and biosimilar technology.
Regional Momentum and Expansion
North America accounts for nearly 40% of demand, driven by strong healthcare infrastructure and adoption of advanced therapies. Europe demonstrates steady growth with specialty clinic and hospital adoption, while Asia-Pacific shows rapid expansion surpassing 25% due to increasing chronic disease prevalence and regulatory approvals. Regional strategies enhance market penetration and competitive positioning.
Future Outlook
The market is projected to sustain robust growth as demand for effective, safe, and patient-friendly oral biologics and biosimilars rises. Stronger partnerships and mergers will reshape competitive landscapes, while continuous innovation ensures improved efficacy, adherence, and accessibility. The future outlook highlights broad expansion supported by healthcare development and technological advancements.
Key players in Oral Biologics and Biosimilars Market include:
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Biocon Ltd.
- Sandoz International GmbH
- Celltrion, Inc.
- Biogen Inc.
- Novo Nordisk A/S
- Oramed Pharmaceuticals, Inc.
- Rani Therapeutics
- Entera Bio Ltd.
- AbbVie Inc.
- Enteris BioPharma, Inc.
In this report, the profile of each market player provides following information:
- Market Share Analysis
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Therapy
- Market Snapshot, By Disease
- Market Snapshot, By Molecule Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Oral Biologics And Biosimilars Market Forces
- Drivers, Restraints and Opportunities
- Drivers
- Advancements in Biotechnology
- Increasing Demand for Targeted Therapies
- Efforts to Improve Patient Access to Biologic Treatments
- Restraints
- Technical Challenges in Oral Drug Delivery
- Regulatory Hurdles for Biosimilar Approval
- Competition from Originator Biologics
- Opportunities
- Expansion of Biosimilar Market
- Growing Aging Population
- Regulatory Initiatives for Streamlined Approval Processes
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Oral Biologics And Biosimilars Market, By Therapy, 2021 - 2031 (USD Million)
- Lymphocyte Modulators
- T-Cell Modulators
- B-Cell Modulators
- Sphingosine-1-Phosphate Receptor Modulators
- Interleukin Inhibitors
- IL-1 Inhibitors
- IL-6 Inhibitors
- IL-17 Inhibitors
- IL-23 Inhibitors
- Tumor Necrosis Factor-Alpha Inhibitors
- TNF-a Blockers
- Monoclonal Antibodies Targeting TNF-a
- Immunostimulants
- Cytokines
- Immune Checkpoint Inhibitors
- Adjuvants
- GPCR Modulators
- Agonists
- Antagonists
- Biased Ligands
- Others
- Lymphocyte Modulators
- Oral Biologics And Biosimilars Market, By Disease, 2021 - 2031 (USD Million)
- Diabetes
- Arthritis & Crohn’s Disease
- Cancer
- Infectious Disease
- Others
- Oral Biologics And Biosimilars Market, By Molecule Type, 2021 - 2031 (USD Million)
- Vaccines
- Proteins & Peptides
- Monoclonal Antibodies
- Others
- Oral Biologics And Biosimilars Market, By Distribution Channel, 2021 - 2031 (USD Million)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Oral Biologics & Biosimilars Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Oral Biologics And Biosimilars Market, By Therapy, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Biocon Ltd.
- Sandoz International GmbH
- Celltrion, Inc.
- Biogen Inc.
- Novo Nordisk A/S
- Oramed Pharmaceuticals, Inc.
- Rani Therapeutics
- Entera Bio Ltd.
- AbbVie Inc.
- Enteris BioPharma, Inc.
- Company Profiles
- Analyst Views
- Future Outlook of the Market